DIM Sartorius Stedim Biotech S.A.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Sartorius Stedim Biotech (EPA: DIM)
›
Sartorius Stedim Biotech (EPA: DIM) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 10,483 employees.
The shares were at 228.60 EUR on 19 November 2026, up 20.8% over 52 weeks. Its 52-week range is 150.00 EUR to 234.00 EUR: the price is 2.3% below the high and 52.4% above the low.
At a market capitalisation of 22.25B EUR, it trades at 68.6 times trailing earnings and 37.7 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 48.1, a premium of 43% for DIM. It pays a dividend yielding 0.31% (it pays out 21% of its earnings), against a median of 1.00% among the dividend payers in that peer group.
Sartorius Stedim Biotech reports return on equity of 6.5%, an operating margin of 19.2% and revenue up 8.0% year over year.
Its debt exceeds its cash by 2.14B EUR, a debt-to-equity ratio of 0.64. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 13 analysts cover the stock; their mean price target of 250.00 EUR is 9.4% above the current price. The next earnings report is expected on 23 February 2027.